Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

V Clini1, G Di Pisa, L Gandola

  • 1Divisione di Pneumologia, Ospedale San Gerardo, Monza, Italy.

Le Infezioni in Medicina
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.

Tumori·1992
Same author

Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study.

Tumori·1992
Same author

Supraspinal influences on recurrent inhibition in humans. Paralysis of descending control of Renshaw cells in patients with mental retardation.

Electroencephalography and clinical neurophysiology·1992
Same author

Expression in murine and human neuroblastoma cell lines of VGF, a tissue specific protein.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·1992
Same author

Calcium entry blockade as a mechanism for chlordimeform-induced inhibition of motor activity in the isolated guinea-pig ileum.

Pharmacology & toxicology·1992
Same author

Energy metabolism of the hypertrophied heart studied by 31P nuclear magnetic resonance.

Cardioscience·1992
Same journal

Rezafungin and catheter-related candidemia: a new player in a high-stakes game.

Le infezioni in medicina·2026
Same journal

Effectiveness and Safety Profile of BIC/TAF/FTC in People living with HIV Switched from Other Antiretroviral Regimens: A Real-Life Retrospective Cohort Analysis.

Le infezioni in medicina·2026
Same journal

Insights into parvovirus B19 clinical and virological dynamics among blood donors.

Le infezioni in medicina·2026
Same journal

When Faster Diagnosis Is Not Enough: Bringing Diagnostic Stewardship into Antimicrobial Stewardship.

Le infezioni in medicina·2026
Same journal

Fragility of Immunisation and Water Systems in Gaza: Infectious Disease Risks in a Conflict-Affected Setting.

Le infezioni in medicina·2026
Same journal

HIV-2 infection in Europe - persistence by migrant flows from West Africa but low spillover into the native population.

Le infezioni in medicina·2026
See all related articles

Cefixime (Suprax) effectively treated exacerbations of chronic bronchitis in a multicenter study. The oral antibiotic demonstrated significant clinical improvements and pathogen eradication with no observed side effects.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Respiratory Medicine

Context:

  • Chronic bronchitis exacerbations represent a significant clinical challenge.
  • Oral antibiotics are crucial for managing bacterial infections in chronic bronchitis.
  • Third-generation cephalosporins offer a valuable therapeutic option.

Purpose:

  • To evaluate the efficacy, safety, and tolerability of once-daily cefixime (Suprax) in patients with chronic bronchitis exacerbation.
  • To assess the impact of cefixime on clinical signs and symptoms of chronic bronchitis.
  • To determine the microbiological eradication rates and radiographic changes associated with cefixime treatment.

Summary:

  • A multicenter study in Italy involved 145 patients (50-85 years) treated with cefixime 400 mg/day for a mean of 7.4 days.

Related Experiment Videos

  • Significant improvements were observed in sputum, cough, dyspnea, fever, bronchospasm, and chest findings (p < 0.05).
  • White blood cell count and leukocyte formula decreased significantly (p < 0.01), and pathogens were eradicated in 94.3% of cases. Radiographic evidence of chronic bronchitis resolved in 75/81 patients (p < 0.01).

    • Impact:

    • Cefixime demonstrated a high overall clinical success rate of 91.7% (133/145 patients).
    • The study highlights cefixime's efficacy and tolerability as a once-daily oral treatment for chronic bronchitis exacerbations.
    • No adverse side effects were reported, suggesting a favorable safety profile for cefixime in this patient population.